3BP and Novartis strike licensing agreement for FAP-targeting peptide technology

Preview

来源: Pharmaceutical Technology

3B Pharmaceuticals (3BP) is a German biotechnology company developing radiopharmaceutical drugs and diagnostics for oncology indications. Credit: stevepb from Pixabay.

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology.

The deal provides Novartis with exclusive rights across the globe to create and commercialise therapeutic and imaging solutions for 3BP’s entire FAP-targeting peptide technology, including FAP-2286.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsAtrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cy... GlobalData

Preview

来源: Pharmaceutical Technology

ReportsClostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indi... GlobalData

View all

3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments. Tiered royalties on net sales are also included in the deal.

3BP continues to hold specific rights to develop its FAP-targeting imaging technology for diagnostic applications.

FAP-2286 is being investigated as a peptide-targeted radionuclide therapy. It is capable of targeting FAP, a significant theranostic target with expression across various types of cancers.

FAP-2286 marks the first peptide-targeted radioligand therapy aiming at FAP to enter clinical development, along with the respective imaging agent.

The therapy candidate is currently under evaluation in the Phase l LuMIERE clinical trial.

3BP nuclear medicine and imaging head Dr Christiane Smerling stated: “We believe the new agreement with Novartis is an ideal partnership for the further clinical development of FAP-2286 for the benefit of patients with many different types of cancer.”

In 2019, 3BP reached a licence and collaboration deal with Clovis Oncology to support the development of a peptide-targeted radiotherapy and imaging agent targeting FAP.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。